Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Cash from Operations (2020 - 2025)

Innate Pharma posted quarterly Cash from Operations of 61409115.62 for Q4 2025, down 733.34% year-on-year from 9696072.28 in Q4 2024, and down 733.34% on a QoQ basis from 7369033.88 in Q4 2024.

Innate Pharma (IPHA) has 6 years of Cash from Operations data on file, last reported at 61409115.62 in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 733.34% year-over-year to 61409115.62; the trailing twelve-month figure through Dec 2025 stood at 116294195.15 (down 56.25% YoY), and the FY2025 full-year result was 61409115.62, down 733.34% from the prior year.
  • Cash from Operations for Q4 2025 stood at 61409115.62, down from 7369033.88 in the prior quarter.
  • Across five years, Cash from Operations topped out at 7369033.88 in Q4 2024 and bottomed at 66873109.89 in Q4 2021.
  • The 5-year median for Cash from Operations is 35031527.5 (2023), against an average of 34319664.26.
  • The widest annual swing landed in 2024, when Cash from Operations jumped 78.96%; it then plunged 733.34% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 66873109.89 in 2021, then jumped by 70.78% to 19542838.28 in 2022, then sank by 79.26% to 35031527.5 in 2023, then soared by 78.96% to 7369033.88 in 2024, then tumbled by 733.34% to 61409115.62 in 2025.
  • The last three Cash from Operations figures came in at 61409115.62 (Q4 2025), 7369033.88 (Q4 2024), and 35031527.5 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -1.67 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.43 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 1.08 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 70.50 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn - -61.41 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -61.41 Mn
Dec 31, 2025 -61.41 Mn
Dec 31, 2024 -7.37 Mn
Dec 31, 2024 -7.37 Mn
Dec 31, 2023 -35.03 Mn
Dec 31, 2023 -35.03 Mn
Jun 30, 2023 -12.48 Mn
Jun 30, 2023 -12.48 Mn
Dec 31, 2022 -19.54 Mn
Dec 31, 2022 -19.54 Mn
Dec 31, 2021 -66.87 Mn
Dec 31, 2021 -66.87 Mn
Jun 30, 2021 -37.53 Mn
Jun 30, 2021 -37.53 Mn
Dec 31, 2020 -61.72 Mn
Dec 31, 2020 -61.72 Mn
Jun 30, 2020 -63.91 Mn
Jun 30, 2020 -63.91 Mn